Right Ventricular Function, Clinical Outcomes, and Effect of Vutrisiran in Transthyretin Amyloidosis With Cardiomyopathy: Insights from the HELIOS-B Trial
Posted inCardiology Clinical Updates news

Right Ventricular Function, Clinical Outcomes, and Effect of Vutrisiran in Transthyretin Amyloidosis With Cardiomyopathy: Insights from the HELIOS-B Trial

This review synthesizes evidence on the prevalence and prognostic value of right ventricular dysfunction in ATTR-CM and the therapeutic impact of vutrisiran on RV function from the HELIOS-B trial, underscoring RV free wall strain as a key biomarker and treatment target.
Prevalence and Prognostic Significance of Restriction Versus Systolic Dysfunction in Patients With Transthyretin and Light Chain Cardiac Amyloidosis
Posted inCardiology Internal Medicine news

Prevalence and Prognostic Significance of Restriction Versus Systolic Dysfunction in Patients With Transthyretin and Light Chain Cardiac Amyloidosis

This large retrospective study of 820 patients reveals that restrictive ventricular physiology is the most common phenotype in cardiac amyloidosis. While preserved LV function offers better initial survival, the rate of progression to restriction is high, emphasizing the need for early clinical detection.
A Unified High-Sensitivity Cardiac Troponin I Threshold of 80 ng/L for Risk Stratification in Wild-Type Transthyretin Amyloid Cardiomyopathy
Posted inCardiology news

A Unified High-Sensitivity Cardiac Troponin I Threshold of 80 ng/L for Risk Stratification in Wild-Type Transthyretin Amyloid Cardiomyopathy

This multicenter study identifies high-sensitivity cardiac troponin I (hs-cTnI) as a potent, independent predictor of mortality in wild-type transthyretin amyloid cardiomyopathy. A universal threshold of 80 ng/L, integrated with natriuretic peptides, provides a robust staging system across multiple assay platforms.
Dual Pathology No Longer a Dead End: Tafamidis and AVR Improve Survival in Aortic Stenosis with Cardiac Transthyretin Amyloidosis
Posted inCardiology news

Dual Pathology No Longer a Dead End: Tafamidis and AVR Improve Survival in Aortic Stenosis with Cardiac Transthyretin Amyloidosis

In a multinational registry of patients with concomitant aortic stenosis (AS) and transthyretin cardiac amyloidosis (ATTR‑CA), both ATTR‑specific therapy (predominantly tafamidis) and aortic valve replacement (AVR) were independently associated with lower mortality. Combined therapy produced outcomes comparable to lone AS treated with AVR.
Transthyretin Cardiac Amyloidosis in Older Black and Hispanic Patients with Heart Failure: Prevalence, Genetics, and Clinical Implications
Posted inCardiology Diabetes & Endocrinology Specialties

Transthyretin Cardiac Amyloidosis in Older Black and Hispanic Patients with Heart Failure: Prevalence, Genetics, and Clinical Implications

A prospective study reveals transthyretin cardiac amyloidosis (ATTR-CA) affects a significant proportion of older Black patients with heart failure, especially men over 75, with nearly half linked to the V142I genetic variant. Hispanic prevalence is lower but still notable.